Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer
- PMID: 28143874
- PMCID: PMC5511549
- DOI: 10.1158/1078-0432.CCR-16-2266
Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer
Abstract
Purpose: Poor body composition metrics (BCM) are associated with inferior cancer outcomes; however, in early breast cancer (EBC), there is a paucity of evidence regarding the impact of BCM on toxicities. This study investigates associations between BCM and treatment-related toxicity in patients with EBC receiving anthracyclines and taxane-based chemotherapy.Experimental Design: Pretreatment computerized tomographic (CT) images were evaluated for skeletal muscle area (SMA), skeletal muscle density (SMD), and fat tissue at the third lumbar vertebrae. Skeletal muscle index (SMI = SMA/height2) and skeletal muscle gauge (SMG = SMI × SMD) were also calculated. Relative risks (RR) are reported for associations between body composition measures and toxicity outcomes, after adjustment for age and body surface area (BSA).Results: BCM were calculated for 151 patients with EBC (median age, 49 years; range, 23-75 years). Fifty patients (33%) developed grade 3/4 toxicity, which was significantly higher in those with low SMI (RR, 1.29; P = 0.002), low SMG (RR, 1.09; P = 0.01), and low lean body mass (RR, 1.48; P = 0.002). Receiver operating characteristic analysis showed the SMG measure to be the best predictor of grade 3/4 toxicity. Dividing SMG into tertiles showed toxicity rates of 46% and 22% for lowest versus highest tertile, respectively (P = 0.005). After adjusting for age and BSA, low SMG (<1,475 units) was significantly associated with hematologic (RR, 2.12; P = 0.02), gastrointestinal grade 3/4 toxicities (RR, 6.49; P = 0.02), and hospitalizations (RR, 1.91; P = 0.05).Conclusions: Poor BCMs are significantly associated with increased treatment-related toxicities. Further studies are needed to investigate how these metrics can be used to more precisely dose chemotherapy to reduce treatment-related toxicity while maintaining efficacy. Clin Cancer Res; 23(14); 3537-43. ©2017 AACR.
©2017 American Association for Cancer Research.
Conflict of interest statement
Figures
Similar articles
-
Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.Clin Cancer Res. 2017 Feb 1;23(3):658-665. doi: 10.1158/1078-0432.CCR-16-0940. Epub 2016 Aug 3. Clin Cancer Res. 2017. PMID: 27489287 Free PMC article.
-
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.JAMA Oncol. 2020 Feb 1;6(2):264-270. doi: 10.1001/jamaoncol.2019.4668. JAMA Oncol. 2020. PMID: 31804676 Free PMC article.
-
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.Am J Clin Oncol. 2009 Aug;32(4):375-80. doi: 10.1097/COC.0b013e31818f2d2f. Am J Clin Oncol. 2009. PMID: 19487917 Clinical Trial.
-
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.Cancer Treat Rev. 2016 Feb;43:19-26. doi: 10.1016/j.ctrv.2015.11.009. Epub 2015 Dec 15. Cancer Treat Rev. 2016. PMID: 26827689 Review.
-
Continued value of adjuvant anthracyclines as treatment for early breast cancer.Lancet Oncol. 2015 Jul;16(7):e362-9. doi: 10.1016/S1470-2045(15)00079-0. Lancet Oncol. 2015. PMID: 26149888 Review.
Cited by
-
Overall survival and short-term efficacy analysis of cervical squamous cell carcinoma with skeletal muscle and 18F-FDG PET/CT parameters.Sci Rep. 2024 Feb 27;14(1):4809. doi: 10.1038/s41598-024-55268-2. Sci Rep. 2024. PMID: 38413662 Free PMC article.
-
Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Cancers (Basel). 2024 Jan 31;16(3):596. doi: 10.3390/cancers16030596. Cancers (Basel). 2024. PMID: 38339347 Free PMC article. Review.
-
Body composition and chemotherapy toxicities in breast cancer: a systematic review of the literature.J Cancer Surviv. 2024 Jan 11. doi: 10.1007/s11764-023-01512-z. Online ahead of print. J Cancer Surviv. 2024. PMID: 38206431 Review.
-
The Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity.Cancers (Basel). 2023 Dec 15;15(24):5856. doi: 10.3390/cancers15245856. Cancers (Basel). 2023. PMID: 38136400 Free PMC article. Review.
-
Comprehensive analysis of ACKR family members in breast cancer using prognostic values.Oncol Lett. 2023 Aug 14;26(4):425. doi: 10.3892/ol.2023.14011. eCollection 2023 Oct. Oncol Lett. 2023. PMID: 37664667 Free PMC article.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66:7–30. - PubMed
-
- SEER. SEER Stat Fact Sheets: Female Breast Cancer. 2015 http://seer.cancer.gov/statfacts/html/breast.html. [updated 2015. Available from: http://seer.cancer.gov/statfacts/html/breast.html.
-
- Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–704. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
